Christoph Klade

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 327 citations

Polycythaemia Vera, Hematology, Clinical Trials +5

Identification of tumor antigens in renal cell carcinoma by serological proteome analysis

Christoph Klade, Tilman Voss, E. Krystek et al. · PROTEOMICS · 2001 · 204 citations

Renal Pathology, Immunology, Pathology +16

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer‐Ausch et al. · Blood · 2015 · 176 citations · Full text

Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis

Oresta Vytvytska, Eszter Nagy, Martin Blüggel et al. · PROTEOMICS · 2002 · 165 citations

Immunology, Staphylococcus Aureus, Proteomics 2001 +19

Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41

Christoph Klade, Heiner Wedemeyer, Thomas Berg et al. · Gastroenterology · 2008 · 153 citations

Vaccination, Therapeutic Vaccination, Vaccine Development +9